Microbiota Laboratory, Clinical Division of Microbiota, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, China Conclusions Patients with UC had an ...

John E Kellow, MD, Associate Professor of Medicine, University of Sydney, Royal North Shore Hospital, St Leonards NSW 2065, Australia. Email: johnk{at}med.usyd.edu.au Many of the symptoms ...

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of ...

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...

Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Correspondence to Professor Hua Peng, Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; hpeng{at}ibp.ac.cn; Professor Yang-Xin Fu, ...

a Inflammatory Bowel Disease Study Group, Royal Free Hospital School of Medicine, London, UK, b Gastroenterology Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK Dr R N Allan, Queen Elizabeth ...

Correspondence to Professor Guy Boeckxstaens, Department of Chronic Diseases, Metabolism, and Ageing, KU Leuven, Leuven, Belgium; guy.boeckxstaens{at}kuleuven.be Objective We evaluated the histamine 1 ...

Faecal immunochemical testing (FIT) has a high sensitivity for the detection of colorectal cancer (CRC). In a symptomatic population FIT may identify those patients who require colorectal ...

The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...